Carriers, components and methods for treatment and / or detection using cll-1 antigen molecules and manipulated immune cells. Claim 1: a chemical antigen receptor, comprising an antigen binding molecule specifically bound to cll-1, wherein the antigen binding molecule comprises at least (a) a variable heavy chain CDR1 containing an amino acid sequence selected from the SEC group. Ibid., Nos. 17, 51, 73 and 95, (b) a variable heavy chain CDR2, including a series of amino acids selected from the SEC group. Ibid., Nos. 18, 52, 74 and 96.(c) A variable heavy chain CDR3 comprising a series of amino acids selected from the SEC group. Ibid., Nos. 19, 53, 75 and 97, (d) a variable light chain CDR1, including a series of amino acids selected from the SEC group. Ibid., Nos. 22, 56, 78 and 100, (E) a variable light chain CDR2, including a series of amino acids selected from the SEC group. Ibid., Nos. 23, 57, 79 and 101, (f) a variable light chain CDR3, including a series of amino acids selected from the SEC group. Ibid., No. 24, 58.Page: 1 Claim 58: an isolated polynucleotide, which encrypts a chemical antigen receptor or T cell receptor,This includes an antigen binding molecule that specifically binds to cll-1, wherein the antigen binding molecule includes a variable light chain CDR3 containing a series of amino acids selected from the SEC group. Ibid., Nos. 24, 58, 80 and 102.Vectores, composiciones y métodos de tratamiento y/o detección utilizando las moléculas de unión al antígeno de CLL-1 y las células inmunes manipuladas. Reivindicación 1: Un receptor de antígeno quimérico que comprende una molécula de unión a antígeno que se une específicamente a CLL-1, en donde la molécula de unión a antígeno comprende al menos uno de: a) una CDR1 de cadena pesada variable que comprende una secuencia de aminoácidos seleccionada del grupo que consiste en las SEC. ID. Nº 17, 51, 73 y 95, b) una CDR2 de cadena pesada variable que comprende una secuencia de aminoácidos seleccionada del gru
